Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NFATc2 CRISPR/Cas9 KO Plasmid (h): sc-400422
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NFATc2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the NFATc2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NFATc2 Antibody (4G6-G5): sc-7296
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NFATc2 CRISPR/Cas9 KO Plasmid (h) | sc-400422 | 20 µg | $397.00 |
Overview
NFATC2 encodes NFATc2, a calcium/calcineurin-regulated transcription factor that coordinates gene expression programs downstream of T cell receptor signaling and other immunoreceptor pathways. Upon dephosphorylation, NFATc2 translocates to the nucleus and cooperates with AP-1 and other cofactors to regulate cytokine production, activation-induced differentiation, and immune tolerance. NFATc2 activity integrates Ca²⁺ signaling with MAPK and NF-κB crosstalk, shaping lymphocyte proliferation and effector function. Dysregulated NFATC2 signaling has been implicated in inflammatory and autoimmune phenotypes and is also studied for roles in tumor–immune interactions and aberrant transcriptional states in cancer biology.
NFATc2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NFATC2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NFATC2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NFATC2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NFATc2 protein expression.
This CRISPR knockout system enables efficient generation of NFATC2-deficient cell models for investigation of NFATc2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting NFATC2 exon(s) critical for NFATc2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple NFATC2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by NFATc2 CRISPR/Cas9 KO Plasmid (h) and NFATc2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NFATC2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by NFATc2 HDR Plasmid (h) and NFATc2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NFATC2 homology arms to support homology-directed repair at defined NFATC2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.